New personalized vaccine aims to keep head and neck cancer from returning

NCT ID NCT04183166

Ongoing Disease control Sponsor: Transgene Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new personalized immunotherapy called TG4050 for people with advanced head and neck cancer. The treatment is designed to train the immune system to recognize and attack each patient's unique tumor mutations. The goal is to see if it is safe and can help prevent the cancer from coming back after standard treatment. About 80 participants will be randomly assigned to receive TG4050 or no additional treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SQUAMOUS CELL CARCINOMA OF HEAD AND NECK

Contacts and locations

Locations

Aintree University Hospital NHS Fondation Trust

Liverpool, L9 7AL, United Kingdom
Complejo Hospitalario Universitario de Santiago

Santiago de Compostela, 15076, Spain
Hospital Clínico San Carlos

Madrid, 28040, Spain
Hospital Regional Universitario de Málaga - Hospital Civil

Málaga, 29010, Spain
Hospital Universitari Vall d Hebrón

Barcelona, 08035, Spain
Hospital Universitario La Paz

Madrid, 28046, Spain
Hôpital Saint André - CHU de Bordeaux

Bordeaux, 33000, France
Hôpital de la Timone

Marseille, 13000, France
IUCT Toulouse

Toulouse, 31100, France
Institut Català d Oncologia - Hospital Duran i Reynals

Barcelona, 08908, Spain
Institut Curie

Paris, 75005, France
Institut Gustave Roussy

Villejuif, 94805, France
Mayo Clinic Jacksonville

Jacksonville, Florida, 32224, United States
NHS Clatterbridge Cancer Center

Liverpool, L7 8YA, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.